BRIEF-Quince Marks Final Patient Visit in NEAT Phase 3 Study

Reuters12-15

Dec 15 (Reuters) - Quince Therapeutics Inc QNCX.O:

QUINCE THERAPEUTICS ANNOUNCES LAST PATIENT LAST VISIT IN PHASE 3 NEAT CLINICAL TRIAL IN PATIENTS WITH ATAXIA-TELANGIECTASIA
QUINCE THERAPEUTICS - EXPECTS TOPLINE RESULTS IN Q1 2026

Source text: ID:nBw3kRP1Da

Further company coverage: QNCX.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2591475266?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-15 22:53","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2591475266","market":"us","top_or_hot":-1,"title":"BRIEF-Quince Marks Final Patient Visit in NEAT Phase 3 Study","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Quince Marks Final Patient Visit in NEAT Phase 3 Study</title></head><body><p><span>Dec 15 (Reuters)</span><span> - </span>Quince <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc <span>QNCX.O</span>:</p><ul><li><p>QUINCE THERAPEUTICS ANNOUNCES LAST PATIENT LAST VISIT IN PHASE 3 NEAT CLINICAL TRIAL IN PATIENTS WITH ATAXIA-TELANGIECTASIA</p></li><li><p>QUINCE THERAPEUTICS - EXPECTS TOPLINE RESULTS IN Q1 2026</p></li></ul><p>Source text: <span>ID:nBw3kRP1Da</span></p><p>Further company coverage: <span>QNCX.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Quince Marks Final Patient Visit in NEAT Phase 3 Study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Quince Marks Final Patient Visit in NEAT Phase 3 Study\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-15 22:53</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Quince Marks Final Patient Visit in NEAT Phase 3 Study</title></head><body><p><span>Dec 15 (Reuters)</span><span> - </span>Quince <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc <span>QNCX.O</span>:</p><ul><li><p>QUINCE THERAPEUTICS ANNOUNCES LAST PATIENT LAST VISIT IN PHASE 3 NEAT CLINICAL TRIAL IN PATIENTS WITH ATAXIA-TELANGIECTASIA</p></li><li><p>QUINCE THERAPEUTICS - EXPECTS TOPLINE RESULTS IN Q1 2026</p></li></ul><p>Source text: <span>ID:nBw3kRP1Da</span></p><p>Further company coverage: <span>QNCX.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"QNCX","symbol_name":"Quince Therapeutics, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251215:nTUA9SHPZW:1","article_id":"2591475266","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2591475266","pubTimestamp":1765810389,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Quince Marks Final Patient Visit in NEAT Phase 3 StudyDec 15 (Reuters) - Quince Therapeutics Inc QNCX.O:QUINCE THERAPEUTICS ANNOUNCES LAST PATIENT LAST VISIT IN PHASE 3 NEAT CLINICAL TRIAL IN PA","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"QNCX":"Quince Therapeutics, Inc.","BK4139":"生物科技"},"translate_title":"BRIEF-Quince标志着NEAT 3期研究的最终患者访视","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"QNCX":0.9},"content_text":"BRIEF-Quince Marks Final Patient Visit in NEAT Phase 3 StudyDec 15 (Reuters) - Quince Therapeutics Inc QNCX.O:QUINCE THERAPEUTICS ANNOUNCES LAST PATIENT LAST VISIT IN PHASE 3 NEAT CLINICAL TRIAL IN PATIENTS WITH ATAXIA-TELANGIECTASIAQUINCE THERAPEUTICS - EXPECTS TOPLINE RESULTS IN Q1 2026Source text: ID:nBw3kRP1DaFurther company coverage: QNCX.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2591475266","isCrawlerRequest":true}